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Abstract—This study presents the recent 
development of three-dimensional 
patient-specific simulation of carmustine 
delivery to brain tumor that highlights 
several crucial factors affecting the 
delivery. The simulation utilizes the full-
brain three-dimensional geometry 
constructed from magnetic resonance 
images (MRI) of a brain tumor patient. 
Prior to the simulation with tumor, the 
baseline simulation is initially done to 
obtain the interstitial fluid homeostasis 
in the normal brain so that the real 
picture of brain fluid dynamics in 
human brain is obtained. The 
simulation is conducted by coupling 
equations of continuity, motion, and 
carmustine species conservation, which, 
in turn, are solved simultaneously to 
calculate pressure, flow, and drug 
concentration fields, respectively. 
Carmustine is delivered by using the 
commercially available “Gliadel” 
wafers following the surgical removal of 
the tumor. The possible effects of 
vasogenic edema (due to surgery 
trauma) to brain fluid dynamics is also 
included. Here, the compiled results 
highlight that the drug release profile is, 
if not more than, as important as the 
dosage and the possible increase of 
convection due to edema. This study 
also reveals that a new strategy, namely 
convection enhanced delivery (CED) is 
able to increase drug penetration by 
enhancing interstitial fluid convection; 
but, over-enhanced convection may 
cause toxicity complications to 
surrounding healthy tissue during later 
stages of treatment. 
 
